
Pfizer in talks with Centre to expedite approval pathway for vaccine
The firm is donating medicines worth $70 million (over Rs 510 crore) for treatment of Covid-19 patients in India

“We are deeply concerned by the critical Covid-19 situation in India, and our hearts go out to you, your loved ones and all the people of India,” he said in a mail sent to Pfizer India employees that he posted on linked.in.
“These medicines, valued at more than $70 million, will be made available immediately, and we will work closely with the government and our NGO partners to get them to where they are needed most,” Bourla said.
Capgemini funds
IT major Capgemini on Monday announced a Rs 50 crore fund to build Covid care ICU facilities, oxygen generation plants, other long-term medical infrastructure and provide relief operations during the pandemic.
In addition, the French firm is also contributing Rs 5 crore to UNICEF to provide immediate support across India for critical Covid-19 response care, by setting up three oxygen generation plants and RT-PCR testing machines.
FM caution
Cautioning the global community against vaccine nationalism at this hour of the pandemic, India on Monday asked the developed nations to share technology and allow free movement of critical components and raw material needed for production of vaccines. “Countries will have to be open about sharing vaccine-based technologies. The TRIPS agreement will have to be looked at in the context of the pandemic,” finance minister Nirmala Sitharaman said.
IGST waiver
0 Response to " Pfizer in talks with Centre to expedite approval pathway for vaccine"
Post a Comment
Disclaimer Note:
The views expressed in the articles published here are solely those of the author and do not necessarily reflect the official policy, position, or perspective of Kalimpong News or KalimNews. Kalimpong News and KalimNews disclaim all liability for the published or posted articles, news, and information and assume no responsibility for the accuracy or validity of the content.
Kalimpong News is a non-profit online news platform managed by KalimNews and operated under the Kalimpong Press Club.
Comment Policy:
We encourage respectful and constructive discussions. Please ensure decency while commenting and register with your email ID to participate.
Note: only a member of this blog may post a comment.